Işıl Altıntaş

981 total citations
13 papers, 541 citations indexed

About

Işıl Altıntaş is a scholar working on Oncology, Radiology, Nuclear Medicine and Imaging and Molecular Biology. According to data from OpenAlex, Işıl Altıntaş has authored 13 papers receiving a total of 541 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Oncology, 6 papers in Radiology, Nuclear Medicine and Imaging and 5 papers in Molecular Biology. Recurrent topics in Işıl Altıntaş's work include Monoclonal and Polyclonal Antibodies Research (6 papers), Nanoparticle-Based Drug Delivery (5 papers) and Glycosylation and Glycoproteins Research (4 papers). Işıl Altıntaş is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (6 papers), Nanoparticle-Based Drug Delivery (5 papers) and Glycosylation and Glycoproteins Research (4 papers). Işıl Altıntaş collaborates with scholars based in Netherlands, United States and Germany. Işıl Altıntaş's co-authors include Raymond M. Schiffelers, Robbert J. Kok, Wim E. Hennink, Paul M.P. van Bergen en Henegouwen, Roy van der Meel, Raimond Heukers, Gert Storm, Rob Haselberg, Rob C. Roovers and Sabrina Oliveira and has published in prestigious journals such as Angewandte Chemie International Edition, SHILAP Revista de lepidopterología and Biomaterials.

In The Last Decade

Işıl Altıntaş

13 papers receiving 533 citations

Peers

Countries citing papers authored by Işıl Altıntaş

Since Specialization

Citations

This map shows the geographic impact of Işıl Altıntaş's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Işıl Altıntaş with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Işıl Altıntaş more than expected).

Fields of papers citing papers by Işıl Altıntaş

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Işıl Altıntaş. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Işıl Altıntaş. The network helps show where Işıl Altıntaş may publish in the future.

Co-authorship network of co-authors of Işıl Altıntaş

This figure shows the co-authorship network connecting the top 25 collaborators of Işıl Altıntaş. A scholar is included among the top collaborators of Işıl Altıntaş based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Işıl Altıntaş. Işıl Altıntaş is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

13 of 13 papers shown

#	Work	Indexed citations
1	Abstract 5071: Minimal residual disease (MRD) status by peripheral blood mononuclear cells (PBMCs) and circulating tumor DNA (ctDNA) demonstrates rapid, deep, and sustained response in patients (Pts) with relapsed/refractory follicular lymphoma (R/R FL) treated with subcutaneous (SC) epcoritamab monotherapy in the pivotal phase 1/2 EPCORE™ NHL-1 trial 2024 ·Cancer Research ·(unknown), Işıl Altıntaş, John Karavitis, Kim Linton, Wojciech Jurczak, Catherine Thiéblemont, Kevin Zhao, Edith Szafer‐Glusman, Daniela Hoehn, Elena Favaro, Mariana Sacchi, Maria Jure‐Kunkel	1
2	Abstract 1846: DuoBody-CD40×4-1BB (GEN1042) induces dendritic-cell maturation and enhances T-cell activation and effector functions in vitro by conditional CD40 and 4-1BB agonist activity 2021 ·Cancer Research ·Alexander Muik, Rachelle Kosoff, Friederike Gieseke, Işıl Altıntaş, (unknown), Saskia M. Burm, Eliana Stanganello, Fulvia Vascotto, Aras Toker, Homer Adams, Esther C.W. Breij, Mustafa Diken, Tahamtan Ahmadi, Kate Sasser, Özlem Türeci, Mark Fereshteh, Uğur Şahin, Maria Jure‐Kunkel	2
3	561 DuoBody®-PD-L1×4–1BB (GEN1046) induces superior immune-cell activation, cytokine production and cytotoxicity by combining PD-L1 blockade with conditional 4–1BB co-stimulation 2020 ·SHILAP Revista de lepidopterología ·Alexander Muik, Işıl Altıntaş, Rachelle Kosoff, Friederike Gieseke, (unknown), Theodora W. Salcedo, Saskia M. Burm, Aras Toker, Lena M. Kranz, Mathias Vormehr, David Eisel, Mark Fereshteh, Özlem Türeci, Esther C.W. Breij, Tahamtan Ahmadi, Uğur Şahin, Maria Jure‐Kunkel	2
4	CD3-Bispecific Antibody Therapy Turns Solid Tumors into Inflammatory Sites but Does Not Install Protective Memory 2018 ·Molecular Cancer Therapeutics ·(unknown), Işıl Altıntaş, Marjolein Sluijter, Sandra Verploegen, Aran F. Labrijn, Danita H. Schuurhuis, Mischa Houtkamp, J. Sjef Verbeek, Janine Schuurman, Thorbald van Hall	61
5	Efficient Generation of Bispecific Murine Antibodies for Pre-Clinical Investigations in Syngeneic Rodent Models 2017 ·Scientific Reports ·Aran F. Labrijn, Joyce Meesters, Matthew W. Bunce, Anthony A. Armstrong, Sandeep Somani, (unknown), Mark L. Chiu, Işıl Altıntaş, Sandra Verploegen, Janine Schuurman, Paul W.H.I. Parren	31
6	Targeting hepatocyte growth factor receptor (Met) positive tumor cells using internalizing nanobody-decorated albumin nanoparticles 2013 ·Biomaterials ·Raimond Heukers, Işıl Altıntaş, (unknown), (unknown), (unknown), Rob C. Roovers, Rob Haselberg, Wim E. Hennink, Raymond M. Schiffelers, Robbert J. Kok, Paul M.P. van Bergen en Henegouwen	71
7	Inhibition of Tumor Growth by Targeted Anti-EGFR/IGF-1R Nanobullets Depends on Efficient Blocking of Cell Survival Pathways 2013 ·Molecular Pharmaceutics ·Roy van der Meel, Sabrina Oliveira, Işıl Altıntaş, Raimond Heukers, Ebel H. E. Pieters, Paul M.P. van Bergen en Henegouwen, Gert Storm, Wim E. Hennink, Robbert J. Kok, Raymond M. Schiffelers	30
8	Nanobody-albumin nanoparticles (NANAPs) for the delivery of a multikinase inhibitor 17864 to EGFR overexpressing tumor cells 2012 ·Journal of Controlled Release ·Işıl Altıntaş, Raimond Heukers, Roy van der Meel, M. Lacombe, Maryam Amidi, Paul M.P. van Bergen en Henegouwen, Wim E. Hennink, Raymond M. Schiffelers, Robbert J. Kok	97
9	Glucocorticoid‐Loaded Core‐Cross‐Linked Polymeric Micelles with Tailorable Release Kinetics for Targeted Therapy of Rheumatoid Arthritis 2012 ·Angewandte Chemie International Edition ·Bart J. Crielaard, Cristianne J.F. Rijcken, (unknown), Steffen van der Wal, Işıl Altıntaş, (unknown), John A. W. Kruijtzer, Rob M. J. Liskamp, Raymond M. Schiffelers, Cornelus F. van Nostrum, Wim E. Hennink, Dong Wang, Twan Lammers, Gert Storm	110
10	Glucocorticoid‐Loaded Core‐Cross‐Linked Polymeric Micelles with Tailorable Release Kinetics for Targeted Therapy of Rheumatoid Arthritis 2012 ·Angewandte Chemie ·Bart J. Crielaard, Cristianne J.F. Rijcken, (unknown), Steffen van der Wal, Işıl Altıntaş, (unknown), John A. W. Kruijtzer, Rob M. J. Liskamp, Raymond M. Schiffelers, Cornelus F. van Nostrum, Wim E. Hennink, Dong Wang, Twan Lammers, Gert Storm	16
11	Targeting epidermal growth factor receptor in tumors: From conventional monoclonal antibodies via heavy chain-only antibodies to nanobodies 2011 ·European Journal of Pharmaceutical Sciences ·Işıl Altıntaş, Robbert J. Kok, Raymond M. Schiffelers	34
12	Tumor-targeted Nanobullets: Anti-EGFR nanobody-liposomes loaded with anti-IGF-1R kinase inhibitor for cancer treatment 2011 ·Journal of Controlled Release ·Roy van der Meel, Sabrina Oliveira, Işıl Altıntaş, Rob Haselberg, Joris van der Veeken, Rob C. Roovers, Paul M.P. van Bergen en Henegouwen, Gert Storm, Wim E. Hennink, Raymond M. Schiffelers, Robbert J. Kok	84
13	Targeted Delivery of Kinase Inhibitors: A Nanomedicine Approach for Improved Selectivity in Cancer 2011 ·Current Signal Transduction Therapy ·Işıl Altıntaş, Raymond M. Schiffelers, Robbert J. Kok	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact